• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于前列腺特异性膜抗原正电子发射断层扫描(PSMA-PET)得出的距离特征作为预测前列腺癌根治术后原发性前列腺癌预后的生物标志物。

PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy.

作者信息

Chen Ruohua, Li Ye, Liang Dong, Liu Jianjun, Sun Tao

机构信息

Department of Nuclear Medicine, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, 160 Pujian Road, Shanghai, China.

Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 1068 Xueyuan Avenue, Shenzhen, Guangdong, China.

出版信息

Cancer Imaging. 2025 Jul 22;25(1):93. doi: 10.1186/s40644-025-00907-8.

DOI:10.1186/s40644-025-00907-8
PMID:40696478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12281684/
Abstract

OBJECTIVES

This study aims to assess the predictive capability of PSMA-PET imaging for disease outcomes in primary prostate cancer post-radical prostatectomy. In addition to conventional lesion uptake measures, the evaluation includes the distance of lesion to the prostate to enhance risk stratification and outcome prediction.

METHODS

A cohort of 190 men diagnosed with primary prostate cancer and undergoing prostatectomy were initially screened, resulting in 103 patients meeting the selection criteria. Imaging parameters, including lesion SUVmax, primary metabolic tumor volume (PMTV), maximum distance from the lesion to the prostate (Dmax), and total distances from the lesion to the prostate (Dtotal), were extracted from 68Ga-PSMA-11 PET images. Findings were dichotomized based on primary lesion uptake, the tumor volume size, Dmax distance, and the presence of metastatic disease. Postoperative biochemical recurrence-free survival (BCRFS) was analyzed using Kaplan-Meier survival plots and Log-rank tests. Furthermore, univariate and multivariate Cox regression analyses were performed to evaluate the association of PET parameters with survival outcomes.

RESULTS

Clinical and histopathological characteristics were summarized, including age, weight, height, metastasis status, baseline PSA, biopsy Gleason score, pt stage, margin status, and lymph node status. After a median follow-up of 20 months, 66 events occurred, with the estimated 3-year BCRFS being 46%. Increased PSMA intensity (SUVmax > 17.06) was associated with less favorable BCRFS (log-rank p = 0.017). Increased primary metabolic tumor volume (PMTV > 41.59 cm) was also linked to less favorable BCRFS (log-rank p = 0.003). Dmax and Dtotal greater than 9.69 cm and 11.95 cm were identified as negative prognostic factors for BCRFS (log-rank p < 0.001 and p = 0.002, respectively). Based on PMTV and Dmax, patients were stratified into low-, intermediate-, and high-risk groups, with 3-year BCRFS rates of 57%, 31%, and 8%, respectively. Univariate Cox regression analysis revealed significant associations between BCRFS and factors such as baseline PSA (HR: 1.69, 95% CI 1.02-2.79, p = 0.042), SUVmax (HR: 1.56, 95% CI 1.04-1.91, p = 0.018), PMTV (HR: 2.05, 95% CI 1.26-3.34, p = 0.004), Dmax (HR: 2.24, 95% CI 1.37-3.65, p = 0.001), and Dtotal (HR: 2.11, 95% CI 1.29-3.45, p = 0.003). Multivariable Cox regression analysis identified the best model with PMTV (HR: 2.57, p = 0.004) and Dmax (HR: 1.98, p = 0.009) as independent predictors for biochemical recurrence (C-index = 0.68).

CONCLUSION

The lesion distance to prostate was defined and assessed in conjunction with conventional PET parameters to facilitate preoperative risk stratification in primary prostate cancer following radical prostatectomy. The findings contribute to improved outcome prediction and emphasize the potential of PSMA-PET imaging in enhancing management strategies for prostate cancer patients.

CLINICAL RELEVANCE

There is a critical need for non-invasive biomarkers that can predict treatment outcomes for patients with primary prostate cancer. Our study introduces the concept of using distance metrics, specifically the lesion distance to prostate in baseline PSMA-PET scans, to improve the prediction of biochemical recurrence following prostatectomy. These distance metrics consider the spatial distribution of lesions, offering a novel approach to assessing tumor spread and its implications for patient outcomes.

摘要

目的

本研究旨在评估PSMA-PET成像对根治性前列腺切除术后原发性前列腺癌疾病预后的预测能力。除了传统的病灶摄取测量外,评估还包括病灶到前列腺的距离,以加强风险分层和预后预测。

方法

对190例诊断为原发性前列腺癌并接受前列腺切除术的男性进行初步筛查,最终103例患者符合入选标准。从68Ga-PSMA-11 PET图像中提取成像参数,包括病灶SUVmax、原发性代谢肿瘤体积(PMTV)、病灶到前列腺的最大距离(Dmax)以及病灶到前列腺的总距离(Dtotal)。根据原发性病灶摄取、肿瘤体积大小、Dmax距离和转移疾病的存在情况将结果进行二分法分类。使用Kaplan-Meier生存曲线和对数秩检验分析术后无生化复发生存期(BCRFS)。此外,进行单变量和多变量Cox回归分析以评估PET参数与生存结果的关联。

结果

总结了临床和组织病理学特征,包括年龄、体重、身高、转移状态、基线PSA、活检Gleason评分、pt分期、切缘状态和淋巴结状态。中位随访20个月后,发生66例事件,估计3年BCRFS为46%。PSMA强度增加(SUVmax>17.06)与较差的BCRFS相关(对数秩p = 0.017)。原发性代谢肿瘤体积增加(PMTV>41.59 cm)也与较差的BCRFS相关(对数秩p = 0.003)。Dmax和Dtotal大于9.69 cm和11.95 cm被确定为BCRFS的阴性预后因素(对数秩p分别<0.001和p = 0.002)。基于PMTV和Dmax,将患者分为低、中、高风险组,3年BCRFS率分别为57%、31%和8%。单变量Cox回归分析显示BCRFS与基线PSA(HR:1.69,95%CI 1.02 - 2.79,p = 0.042)、SUVmax(HR:1.56,95%CI 1.04 - 1.91,p = 0.018)、PMTV(HR:2.05,95%CI 1.26 - 3.34,p = 0.004)、Dmax(HR:2.24,95%CI 1.37 - 3.65,p = 0.001)和Dtotal(HR:2.11,95%CI 1.29 - 3.45,p = 0.003)等因素之间存在显著关联。多变量Cox回归分析确定最佳模型,其中PMTV(HR:2.57,p = 0.004)和Dmax(HR:1.98,p = 0.009)作为生化复发的独立预测因子(C指数 = 0.68)。

结论

结合传统PET参数定义并评估病灶到前列腺的距离,以促进根治性前列腺切除术后原发性前列腺癌的术前风险分层。这些发现有助于改善预后预测,并强调PSMA-PET成像在加强前列腺癌患者管理策略方面的潜力。

临床意义

迫切需要能够预测原发性前列腺癌患者治疗结果的非侵入性生物标志物。我们的研究引入了使用距离指标的概念,特别是基线PSMA-PET扫描中病灶到前列腺的距离,以改善前列腺切除术后生化复发的预测。这些距离指标考虑了病灶的空间分布,为评估肿瘤扩散及其对患者预后的影响提供了一种新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9702/12281684/796ea3c64071/40644_2025_907_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9702/12281684/41ec971b4605/40644_2025_907_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9702/12281684/eba70c8e6fc0/40644_2025_907_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9702/12281684/452035c9e902/40644_2025_907_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9702/12281684/796ea3c64071/40644_2025_907_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9702/12281684/41ec971b4605/40644_2025_907_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9702/12281684/eba70c8e6fc0/40644_2025_907_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9702/12281684/452035c9e902/40644_2025_907_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9702/12281684/796ea3c64071/40644_2025_907_Fig4_HTML.jpg

相似文献

1
PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy.基于前列腺特异性膜抗原正电子发射断层扫描(PSMA-PET)得出的距离特征作为预测前列腺癌根治术后原发性前列腺癌预后的生物标志物。
Cancer Imaging. 2025 Jul 22;25(1):93. doi: 10.1186/s40644-025-00907-8.
2
The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.68Ga-PSMA PET/CT扫描在前列腺癌初次治疗后生化复发中的作用:文献系统综述
Minerva Urol Nefrol. 2018 Oct;70(5):462-478. doi: 10.23736/S0393-2249.18.03081-3. Epub 2018 Apr 17.
3
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.阴性前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描能否避免新诊断前列腺癌患者进行盆腔淋巴结清扫?一项以病理组织学为参考标准的系统评价和Meta分析
Eur Urol Oncol. 2022 Feb;5(1):1-17. doi: 10.1016/j.euo.2021.08.001. Epub 2021 Sep 17.
4
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis.前列腺特异性膜抗原正电子发射断层扫描在评估根治性治疗后前列腺癌生化复发患者局部复发和远处转移中的作用:一项系统评价和荟萃分析。
Eur Urol. 2025 May 19. doi: 10.1016/j.eururo.2025.05.006.
5
Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence.多中心外部验证及对前列腺特异性膜抗原PET/CT在生化复发中准确性的拟用列线图的优化
Prostate. 2025 Aug;85(11):1016-1023. doi: 10.1002/pros.24910. Epub 2025 May 6.
6
The value of habitat analysis based on F-PSMA-1007 PET/CT images for prostate cancer risk grading.基于F-PSMA-1007 PET/CT图像的前列腺癌风险分级的栖息地分析价值。
BMC Med Imaging. 2025 Jul 21;25(1):293. doi: 10.1186/s12880-025-01829-4.
7
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.常规影像学检查无转移疾病的高危生化复发前列腺癌患者的PSMA-PET/CT表现
JAMA Netw Open. 2025 Jan 2;8(1):e2452971. doi: 10.1001/jamanetworkopen.2024.52971.
8
The tumour sink effect on Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study.肿瘤对转移性去势抵抗性前列腺癌中镓-PSMA-PET/CT的汇聚效应及其对PSMA-RPT的意义:3TMPO研究的亚分析
Cancer Imaging. 2025 Jul 15;25(1):91. doi: 10.1186/s40644-025-00910-z.
9
Comparison of F-based PSMA radiotracers with [Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis.F 基 PSMA 放射性示踪剂与 [Ga]Ga-PSMA-11 在前列腺癌 PET/CT 成像中的比较:系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2024 Dec;27(4):654-664. doi: 10.1038/s41391-023-00755-2. Epub 2023 Nov 28.
10
A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment.前列腺特异性膜抗原正电子发射断层扫描在前列腺癌明确治疗前诊断和初始分期中作用的综合系统评价与荟萃分析
Eur Urol. 2025 Jun;87(6):654-671. doi: 10.1016/j.eururo.2025.03.003. Epub 2025 Mar 27.

本文引用的文献

1
Size and SUV define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer.大小和标准化摄取值定义了寡复发前列腺癌中淋巴结转移对前列腺特异性抗原的影响。
Prostate. 2025 Jan;85(1):105-111. doi: 10.1002/pros.24806. Epub 2024 Oct 9.
2
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.联合 PSMA-PET 和 PROMISE 重新定义前列腺癌患者的疾病分期和风险:一项多中心回顾性研究。
Lancet Oncol. 2024 Sep;25(9):1188-1201. doi: 10.1016/S1470-2045(24)00326-7. Epub 2024 Jul 29.
3
Development of a Visually Calculated SUV (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to Lu-PSMA Therapy: Comparison with Quantitative SUV and Patient Outcomes.
开发一种基于 PSMA PET/CT 筛查的视觉计算 SUV(HIT 评分)以预测 Lu-PSMA 治疗反应:与定量 SUV 和患者预后的比较。
J Nucl Med. 2024 Jun 3;65(6):904-908. doi: 10.2967/jnumed.123.267014.
4
Multiparametric MRI-based 5-year Risk Prediction Model for Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy.基于多参数 MRI 的前列腺癌根治术后生化复发 5 年风险预测模型。
Radiology. 2023 Nov;309(2):e223349. doi: 10.1148/radiol.223349.
5
TotalSegmentator: Robust Segmentation of 104 Anatomic Structures in CT Images.全段分割器:CT图像中104种解剖结构的稳健分割
Radiol Artif Intell. 2023 Jul 5;5(5):e230024. doi: 10.1148/ryai.230024. eCollection 2023 Sep.
6
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.根治性治疗后前列腺癌患者的生化复发:基于风险分层的治疗。
Prostate Cancer Prostatic Dis. 2024 Jun;27(2):192-201. doi: 10.1038/s41391-023-00712-z. Epub 2023 Sep 7.
7
Node Oligorecurrence in Prostate Cancer: A Challenge.前列腺癌中的寡转移复发:一项挑战
Cancers (Basel). 2023 Aug 17;15(16):4159. doi: 10.3390/cancers15164159.
8
Presurgical Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.术前 Ga-PSMA-11 正电子发射断层扫描用于生化复发风险评估:一项多中心前瞻性 3 期成像试验的随访分析。
Eur Urol. 2023 Dec;84(6):588-596. doi: 10.1016/j.eururo.2023.06.022. Epub 2023 Jul 21.
9
F-FDG PET/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor?淋巴瘤中F-FDG PET/CT的最大肿瘤播散(Dmax):一种新的预后因素?
Cancers (Basel). 2023 Apr 26;15(9):2494. doi: 10.3390/cancers15092494.
10
Using PSMA imaging for prognostication in localized and advanced prostate cancer.利用前列腺特异性膜抗原(PSMA)成像对局限性和晚期前列腺癌进行预后评估。
Nat Rev Urol. 2023 Jan;20(1):23-47. doi: 10.1038/s41585-022-00670-6. Epub 2022 Dec 6.